Abstract:Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing. Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing.

Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort

Performance of a Protein Language Model for Variant Annotation in Cardiac Disease

Abstract 2267: Assessment of AlphaMissense and structure-function predictions demonstrates efficient reclassification of genetic variants of unknown pathogenicity in inherited myeloid neoplasms

Evaluating novel in silico tools for accurate pathogenicity classification in epilepsy‐associated genetic missense variants

Clinical Utility of Protein Language Models in Resolution of Variants of Uncertain Significance in KCNQ1, KCNH2, and SCN5A Compared With Patch-Clamp Functional Characterization

REVEL: an Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants

Assessing the Utility of ColabFold and AlphaMissense in Determining Missense Variant Pathogenicity for Congenital Myasthenic Syndromes

Understanding structure-guided variant effect predictions using 3D convolutional neural networks

The landscape of regional missense mutational intolerance quantified from 125,748 exomes

The performance of AlphaMissense to identify genes causing disease

Leveraging cancer mutation data to predict the pathogenicity of germline missense variants

Assessment of variant effect predictors unveils variants difficulty as a critical performance indicator

Major Causes of Conflicting Interpretations of Variant Pathogenicity in Rare Disease: A Systematic Analysis

The performance of AlphaMissense to identify genes influencing disease

A New Era in Missense Variant Analysis: Statistical Insights and the Introduction of VAMPP-Score for Pathogenicity Assessment

Functional characterization of all missense variants and comparison to in silico models of pathogenicity

VariPred: Enhancing Pathogenicity Prediction of Missense Variants Using Protein Language Models

Evaluation of an Automated Genome Interpretation Model for Rare Disease Routinely Used in a Clinical Genetic Lab

Critical assessment of missense variant effect predictors on disease-relevant variant data

A comparative medical genomics approach may facilitate the interpretation of rare missense variation